Edgewise Therapeutics, Inc. - 8-K Filing
Edgewise Therapeutics agreed to sell its sevasemten compound and related neuromuscular program assets to Servier Pharmaceuticals for $1.55 billion in upfront cash, with potential additional milestone payments of up to $1.1 billion tied to regulatory approvals and sales thresholds. The transaction is expected to close by Q3 2026, allowing Edgewise to focus on its cardiovascular pipeline. (Items: 1.01 Entry into a Material Definitive Agreement On June 1, 2026, Edgewise Therapeutics, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit No)
Tickers: $EWTX